Additionally, inhibition of the EphB4-ephrin-B2 pathway in experimental HNSCC models led to the reprogramming of the tumor immune microenvironment, suggesting that targeting this system could alter tumor ecology and reduce immune evasion (38). The gene discussed is EPHB4; the disease is neoplasm.